## Zabrina L Brumme

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6298892/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Changes in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients. New England Journal of Medicine, 2002, 346, 811-820.	27.0	591
2	Adaptation of HIV-1 to human leukocyte antigen class I. Nature, 2009, 458, 641-645.	27.8	408
3	Predictors of HIV Drugâ€Resistance Mutations in a Large Antiretroviralâ€Naive Cohort Initiating Triple Antiretroviral Therapy. Journal of Infectious Diseases, 2005, 191, 339-347.	4.0	386
4	Influence of HLA-C Expression Level on HIV Control. Science, 2013, 340, 87-91.	12.6	352
5	Whole Genome Deep Sequencing of HIV-1 Reveals the Impact of Early Minor Variants Upon Immune Recognition During Acute Infection. PLoS Pathogens, 2012, 8, e1002529.	4.7	306
6	HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphotye Recognition. Journal of Virology, 2009, 83, 2743-2755.	3.4	261
7	Molecular and Clinical Epidemiology of CXCR4â€Using HIVâ€1 in a Large Population of Antiretroviralâ€Naive Individuals. Journal of Infectious Diseases, 2005, 192, 466-474.	4.0	260
8	Antigen Load and Viral Sequence Diversification Determine the Functional Profile of HIV-1–Specific CD8+ T Cells. PLoS Medicine, 2008, 5, e100.	8.4	205
9	TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nature Immunology, 2012, 13, 691-700.	14.5	203
10	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Medicine, 2015, 12, e1001810.	8.4	188
11	Marked Epitope- and Allele-Specific Differences in Rates of Mutation in Human Immunodeficiency Type 1 (HIV-1) Gag, Pol, and Nef Cytotoxic T-Lymphocyte Epitopes in Acute/Early HIV-1 Infection. Journal of Virology, 2008, 82, 9216-9227.	3.4	162
12	Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1. PLoS Pathogens, 2007, 3, e94.	4.7	153
13	HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins. PLoS ONE, 2009, 4, e6687.	2.5	148
14	Definition of the viral targets of protective HIV-1-specific T cell responses. Journal of Translational Medicine, 2011, 9, 208.	4.4	143
15	HIV-1 Vpu Mediates HLA-C Downregulation. Cell Host and Microbe, 2016, 19, 686-695.	11.0	127
16	A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. ELife, 2013, 2, e01123.	6.0	126
17	Human Immunodeficiency Virus Type 1 Protease Cleavage Site Mutations Associated with Protease Inhibitor Cross-Resistance Selected by Indinavir, Ritonavir, and/or Saquinavir. Journal of Virology, 2001, 75, 589-594.	3.4	121
18	Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers. Journal of Virology, 2010, 84, 7581-7591.	3.4	118

#	Article	IF	CITATIONS
19	Phylogenetic Dependency Networks: Inferring Patterns of CTL Escape and Codon Covariation in HIV-1 Gag. PLoS Computational Biology, 2008, 4, e1000225.	3.2	116
20	Genetic Characterization of Human Immunodeficiency Virus Type 1 in Elite Controllers: Lack of Gross Genetic Defects or Common Amino Acid Changes. Journal of Virology, 2008, 82, 8422-8430.	3.4	114
21	Widespread Impact of HLA Restriction on Immune Control and Escape Pathways of HIV-1. Journal of Virology, 2012, 86, 5230-5243.	3.4	114
22	Operationalizing the One Health approach: the global governance challenges. Health Policy and Planning, 2013, 28, 778-785.	2.7	113
23	HLA-Associated Alterations in Replication Capacity of Chimeric NL4-3 Viruses Carrying <i>gag-protease</i> from Elite Controllers of Human Immunodeficiency Virus Type 1. Journal of Virology, 2009, 83, 140-149.	3.4	112
24	Early Selection in Gag by Protective HLA Alleles Contributes to Reduced HIV-1 Replication Capacity That May Be Largely Compensated for in Chronic Infection. Journal of Virology, 2010, 84, 11937-11949.	3.4	111
25	Attenuation of multiple Nef functions in HIV-1 elite controllers. Retrovirology, 2013, 10, 1.	2.0	102
26	Correlates of Protective Cellular Immunity Revealed by Analysis of Population-Level Immune Escape Pathways in HIV-1. Journal of Virology, 2012, 86, 13202-13216.	3.4	99
27	Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus. PLoS Pathogens, 2016, 12, e1005619.	4.7	97
28	Gag-Protease-Mediated Replication Capacity in HIV-1 Subtype C Chronic Infection: Associations with HLA Type and Clinical Parameters. Journal of Virology, 2010, 84, 10820-10831.	3.4	87
29	Impact of pre-adapted HIV transmission. Nature Medicine, 2016, 22, 606-613.	30.7	87
30	Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. Aids, 2003, 17, 201-208.	2.2	85
31	Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5393-400.	7.1	85
32	HIV-1 adaptation to HLA: a window into virus–host immune interactions. Trends in Microbiology, 2015, 23, 212-224.	7.7	85
33	Efficacious Early Antiviral Activity of HIV Gag- and Pol-Specific HLA-B*2705-Restricted CD8 + T Cells. Journal of Virology, 2010, 84, 10543-10557.	3.4	84
34	Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. Aids, 2004, 18, F1-F9.	2.2	80
35	Suboptimal Biological Sampling as a Probable Cause of False-Negative COVID-19 Diagnostic Test Results. Journal of Infectious Diseases, 2020, 222, 899-902.	4.0	75
36	Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes. Retrovirology, 2013, 10, 100.	2.0	68

#	Article	IF	CITATIONS
37	Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection. Aids, 2008, 22, 1277-1286.	2.2	67
38	HLA-Associated Viral Mutations Are Common in Human Immunodeficiency Virus Type 1 Elite Controllers. Journal of Virology, 2009, 83, 3407-3412.	3.4	67
39	HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. Journal of Clinical Investigation, 2018, 128, 4074-4085.	8.2	67
40	Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. Journal of Infectious Diseases, 2022, 225, 1129-1140.	4.0	65
41	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. Npj Vaccines, 2022, 7, 28.	6.0	64
42	HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). Nature Communications, 2021, 12, 165.	12.8	60
43	Phylogenetic Analysis of Population-Based and Deep Sequencing Data to Identify Coevolving Sites in the nef Gene of HIV-1. Molecular Biology and Evolution, 2010, 27, 819-832.	8.9	59
44	Reduced Replication Capacity of NL4-3 Recombinant Viruses Encoding Reverse Transcriptase–Integrase Sequences From HIV-1 Elite Controllers. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 100-108.	2.1	59
45	Transmission and Long-Term Stability of Compensated CD8 Escape Mutations. Journal of Virology, 2009, 83, 3993-3997.	3.4	58
46	Impact of HLA-B*81-Associated Mutations in HIV-1 Gag on Viral Replication Capacity. Journal of Virology, 2012, 86, 3193-3199.	3.4	57
47	Progression to AIDS in South Africa Is Associated with both Reverting and Compensatory Viral Mutations. PLoS ONE, 2011, 6, e19018.	2.5	57
48	Viral adaptation to immune selection pressure by HLA class l–restricted CTL responses targeting epitopes in HIV frameshift sequences. Journal of Experimental Medicine, 2010, 207, 61-75.	8.5	52
49	Killer cell immunoglobulin–like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. Journal of Clinical Investigation, 2018, 128, 1903-1912.	8.2	52
50	Statistical Resolution of Ambiguous HLA Typing Data. PLoS Computational Biology, 2008, 4, e1000016.	3.2	50
51	Influence of Gag-Protease-Mediated Replication Capacity on Disease Progression in Individuals Recently Infected with HIV-1 Subtype C. Journal of Virology, 2011, 85, 3996-4006.	3.4	50
52	Phylogenetic approach to recover integration dates of latent HIV sequences within-host. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8958-E8967.	7.1	50
53	Host-Specific Adaptation of HIV-1 Subtype B in the Japanese Population. Journal of Virology, 2014, 88, 4764-4775.	3.4	47
54	Genotypic and Functional Impact of HIV-1 Adaptation to Its Host Population during the North American Epidemic. PLoS Genetics, 2014, 10, e1004295.	3.5	45

#	Article	IF	CITATIONS
55	Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury. Critical Care, 2003, 7, R176.	5.8	44
56	HIV evolution in response to HLA-restricted CTL selection pressures: a population-based perspective. Microbes and Infection, 2008, 10, 455-461.	1.9	44
57	Frequent and Variable Cytotoxic-T-Lymphocyte Escape-Associated Fitness Costs in the Human Immunodeficiency Virus Type 1 Subtype B Gag Proteins. Journal of Virology, 2013, 87, 3952-3965.	3.4	43
58	A Mutation in the 3′ Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) Associated with Nonnucleoside Reverse Transcriptase Inhibitor Resistance. Journal of Virology, 2002, 76, 6836-6840.	3.4	42
59	Screening of the Pan-African Natural Product Library Identifies Ixoratannin A-2 and Boldine as Novel HIV-1 Inhibitors. PLoS ONE, 2015, 10, e0121099.	2.5	38
60	Rapid Detection of SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, British Columbia, Canada. Emerging Infectious Diseases, 2021, 27, 1673-1676.	4.3	38
61	No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy. Aids, 2002, 16, 1929-1933.	2.2	37
62	HIV-1 variants are archived throughout infection and persist in the reservoir. PLoS Pathogens, 2020, 16, e1008378.	4.7	37
63	Antiretroviral Resistance among HIVâ€Infected Persons Who Have Died in British Columbia, in the Era of Modern Antiretroviral Therapy. Journal of Infectious Diseases, 2004, 190, 285-292.	4.0	36
64	HLA class I sequence-based typing using DNA recovered from frozen plasma. Journal of Immunological Methods, 2012, 382, 40-47.	1.4	36
65	Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. Aids, 2005, 19, 549-554.	2.2	35
66	A Simple Screening Approach to Reduce B*5701-Associated Abacavir Hypersensitivity on the Basis of Sequence Variation in HIV Reverse Transcriptase. Clinical Infectious Diseases, 2007, 44, 1503-1508.	5.8	35
67	Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection. Scientific Reports, 2013, 3, 3097.	3.3	35
68	HIV Diversity and Genetic Compartmentalization in Blood and Testes during Suppressive Antiretroviral Therapy. Journal of Virology, 2019, 93, .	3.4	35
69	Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression. Journal of Virology, 2017, 91, .	3.4	34
70	Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study. Retrovirology, 2009, 6, 72.	2.0	33
71	Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity. Journal of Virology, 2012, 86, 6913-6923.	3.4	33
72	Impaired Nef Function Is Associated with Early Control of HIV-1 Viremia. Journal of Virology, 2014, 88, 10200-10213.	3.4	33

#	Article	IF	CITATIONS
73	Novel HLA class I associations with HIV-1 control in a unique genetically admixed population. Scientific Reports, 2018, 8, 6111.	3.3	32
74	HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals. Journal of Virology, 2019, 93, .	3.4	32
75	Effects of Human Leukocyte Antigen Class I Genetic Parameters on Clinical Outcomes and Survival after Initiation of Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2007, 195, 1694-1704.	4.0	31
76	Epithelial adhesion molecules can inhibit HIV-1–specific CD8+ T-cell functions. Blood, 2011, 117, 5112-5122.	1.4	31
77	People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. Journal of Infectious Diseases, 2023, 227, 838-849.	4.0	31
78	Aminopeptidase Substrate Preference Affects HIV Epitope Presentation and Predicts Immune Escape Patterns in HIV-Infected Individuals. Journal of Immunology, 2012, 188, 5924-5934.	0.8	30
79	Dynamic range of Nef functions in chronic HIV-1 infection. Virology, 2013, 439, 74-80.	2.4	30
80	Distinct HIV-1 Escape Patterns Selected by Cytotoxic T Cells with Identical Epitope Specificity. Journal of Virology, 2013, 87, 2253-2263.	3.4	30
81	HLA-C downregulation by HIV-1 adapts to host HLA genotype. PLoS Pathogens, 2018, 14, e1007257.	4.7	30
82	CCR5Δ32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response. Aids, 2001, 15, 2259-2266.	2.2	29
83	Factors Associated With Viral Rebound in HIV-1-Infected Individuals Enrolled in a Therapeutic HIV-1 gag Vaccine Trial. Journal of Infectious Diseases, 2011, 203, 976-983.	4.0	29
84	Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products. Viruses, 2018, 10, 348.	3.3	28
85	Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1 Entry Receptors. Journal of Virology, 2015, 89, 9639-9652.	3.4	26
86	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. Clinical Cancer Research, 2016, 22, 2226-2236.	7.0	26
87	Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. Journal of Infectious Diseases, 2022, 226, 983-994.	4.0	26
88	The HIV-1 latent reservoir is largely sensitive to circulating T cells. ELife, 2020, 9, .	6.0	25
89	Immune Screening Identifies Novel T Cell Targets Encoded by Antisense Reading Frames of HIV-1. Journal of Virology, 2015, 89, 4015-4019.	3.4	24
90	CD4-Dependent Characteristics of Coreceptor Use and HIV Type 1 V3 Sequence in a Large Population of Therapy-Naive Individuals. AIDS Research and Human Retroviruses, 2008, 24, 219-228.	1.1	23

#	Article	IF	CITATIONS
91	Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs. Frontiers in Immunology, 2015, 6, 506.	4.8	23
92	Relative Resistance of HLA-B to Downregulation by Naturally Occurring HIV-1 Nef Sequences. MBio, 2016, 7, e01516-15.	4.1	23
93	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncolmmunology, 2017, 6, e1321184.	4.6	23
94	A robust and scalable TCR-based reporter cell assay to measure HIV-1 Nef-mediated T cell immune evasion. Journal of Immunological Methods, 2015, 426, 104-113.	1.4	22
95	Genetic Diversity, Compartmentalization, and Age of HIV Proviruses Persisting in CD4 <sup>+</sup> T Cell Subsets during Long-Term Combination Antiretroviral Therapy. Journal of Virology, 2020, 94, .	3.4	21
96	Evaluation of Nasopharyngeal Swab Collection Techniques for Nucleic Acid Recovery and Participant Experience: Recommendations for COVID-19 Diagnostics. Open Forum Infectious Diseases, 2020, 7, ofaa488.	0.9	21
97	Nef-mediated down-regulation of CD4 and HLA class I in HIV-1 subtype C infection: Association with disease progression and influence of immune pressure. Virology, 2014, 468-470, 214-225.	2.4	20
98	Anti-APOBEC3G Activity of HIV-1 Vif Protein Is Attenuated in Elite Controllers. Journal of Virology, 2015, 89, 4992-5001.	3.4	20
99	Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5. PLoS Pathogens, 2020, 16, e1008813.	4.7	20
100	Impact of Select Immunologic and Virologic Biomarkers on CD4 Cell Count Decrease in Patients with Chronic HIVâ€1 Subtype C Infection: Results from Sinikithemba Cohort, Durban, South Africa. Clinical Infectious Diseases, 2009, 49, 956-964.	5.8	19
101	Consequences of HLA-B*13-Associated Escape Mutations on HIV-1 Replication and Nef Function. Journal of Virology, 2015, 89, 11557-11571.	3.4	19
102	Inhibition of NF-κB-dependent HIV-1 replication by the marine natural product bengamide A. Antiviral Research, 2018, 152, 94-103.	4.1	19
103	A strong association of human leukocyte antigen-associated Pol and Gag mutations with clinical parameters in HIV-1 subtype A/E infection. Aids, 2016, 30, 681-689.	2.2	18
104	Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity. Cell Reports, 2019, 29, 1449-1457.e5.	6.4	18
105	Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth. Aids, 2019, 33, 211-218.	2.2	18
106	Novel Acylguanidine-Based Inhibitor of HIV-1. Journal of Virology, 2016, 90, 9495-9508.	3.4	17
107	Genotypic and Mechanistic Characterization of Subtype-Specific HIV Adaptation to Host Cellular Immunity. Journal of Virology, 2019, 93,	3.4	17
108	SARS-CoV-2 RNA Quantification Using Droplet Digital RT-PCR. Journal of Molecular Diagnostics, 2021, 23, 907-919.	2.8	17

#	Article	IF	CITATIONS
109	In Vitro Selection of Clinically Relevant Bevirimat Resistance Mutations Revealed by "Deep" Sequencing of Serially Passaged, Quasispecies-Containing Recombinant HIV-1. Journal of Clinical Microbiology, 2011, 49, 201-208.	3.9	16
110	Croton megalobotrys Müll Arg. and Vitex doniana (Sweet): Traditional medicinal plants in a three-step treatment regimen that inhibit in vitro replication of HIV-1. Journal of Ethnopharmacology, 2016, 191, 331-340.	4.1	16
111	Extensive host immune adaptation in a concentrated North American HIV epidemic. Aids, 2018, 32, 1927-1938.	2.2	16
112	The Impact of Treatment as Prevention on the HIV Epidemic in British Columbia, Canada. Current HIV/AIDS Reports, 2020, 17, 77-87.	3.1	16
113	Prevalence and clinical implications of insertions in the HIV-1 p6 <sup>Gag</sup> N-terminal region in drug-naive individuals initiating antiretroviral therapy. Antiviral Therapy, 2003, 8, 91-96.	1.0	16
114	Tracking the culprit: HIV-1 evolution and immune selection revealed by single-genome amplification. Journal of Experimental Medicine, 2009, 206, 1215-1218.	8.5	15
115	Early immune adaptation in HIV-1 revealed by population-level approaches. Retrovirology, 2014, 11, 64.	2.0	15
116	Differential evolution of a CXCR4-using HIV-1 strain in CCR5wt/wt and CCR5â^†32/â^†32 hosts revealed by longitudinal deep sequencing and phylogenetic reconstruction. Scientific Reports, 2015, 5, 17607.	3.3	15
117	Immune-mediated attenuation of HIV-1. Future Virology, 2011, 6, 917-928.	1.8	14
118	Significant Reductions in Gag-Protease-Mediated HIV-1 Replication Capacity during the Course of the Epidemic in Japan. Journal of Virology, 2013, 87, 1465-1476.	3.4	14
119	Immune Correlates of Disease Progression in Linked HIV-1 Infection. Frontiers in Immunology, 2019, 10, 1062.	4.8	14
120	Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency. Biochemical Pharmacology, 2021, 186, 114462.	4.4	14
121	HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy. MBio, 2021, 12, e0249021.	4.1	14
122	Short Communication: HIV VprR77Q Mutation Does Not Influence Clinical Response of Individuals Initiating Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2006, 22, 615-618.	1.1	13
123	Switching and emergence of CTL epitopes in HIV-1 infection. Retrovirology, 2014, 11, 38.	2.0	13
124	Modest Attenuation of HIV-1 Vpu Alleles Derived from Elite Controller Plasma. PLoS ONE, 2015, 10, e0120434.	2.5	13
125	Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic. Journal of Virology, 2016, 90, 1244-1258.	3.4	13
126	Mother-to-Child HIV Transmission Bottleneck Selects for Consensus Virus with Lower Gag-Protease-Driven Replication Capacity. Journal of Virology, 2017, 91, .	3.4	13

#	Article	IF	CITATIONS
127	Rapid HIV-1 Disease Progression in Individuals Infected with a Virus Adapted to Its Host Population. PLoS ONE, 2016, 11, e0150397.	2.5	13
128	The impact of human genetic variation on HIV disease in the era of HAART. AIDS Reviews, 2006, 8, 78-87.	1.0	13
129	Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals. Journal of Virology, 2018, 92, .	3.4	12
130	The Croton megalobotrys MÃ1⁄4ll Arg. traditional medicine in HIV/AIDS management: Documentation of patient use, in vitro activation of latent HIV-1 provirus, and isolation of active phorbol esters. Journal of Ethnopharmacology, 2018, 211, 267-277.	4.1	12
131	Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection. Journal of Virology, 2018, 92, .	3.4	12
132	Increasingly Successful Highly Active Antiretroviral Therapy Delays the Emergence of New HLA Class I–Associated Escape Mutations in HIV-1. Clinical Infectious Diseases, 2012, 54, 1652-1659.	5.8	11
133	No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial. PLoS ONE, 2013, 8, e71758.	2.5	11
134	An Evaluation of Phylogenetic Methods for Reconstructing Transmitted HIV Variants using Longitudinal Clonal HIV Sequence Data. Journal of Virology, 2014, 88, 6181-6194.	3.4	11
135	High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia. Viruses, 2018, 10, 60.	3.3	11
136	Longitudinal within-host evolution of HIV Nef-mediated CD4, HLA and SERINC5 downregulation activity: a case study. Retrovirology, 2020, 17, 3.	2.0	10
137	2-Trifluoromethylthiazole-5-carboxamides: Analogues of a Stilbene-Based Anti-HIV Agent that Impact HIV mRNA Processing. ACS Medicinal Chemistry Letters, 2021, 12, 1818-1823.	2.8	10
138	Intersubtype Differences in the Effect of a Rare p24 Gag Mutation on HIV-1 Replicative Fitness. Journal of Virology, 2012, 86, 13423-13433.	3.4	9
139	Minor contribution of HLA class I-associated selective pressure to the variability of HIV-1 accessory protein Vpu. Biochemical and Biophysical Research Communications, 2012, 421, 291-295.	2.1	9
140	Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia. Viruses, 2019, 11, 877.	3.3	9
141	A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. Journal of Experimental Medicine, 2021, 218, .	8.5	9
142	Lack of Association between HLA Class II Alleles and <i>In Vitro</i> Replication Capacities of Recombinant Viruses Encoding HIV-1 Subtype C Gag-Protease from Chronically Infected Individuals. Journal of Virology, 2012, 86, 1273-1276.	3.4	8
143	Modulation of HIV reservoirs by host HLA: bridging the gap between vaccine and cure. Current Opinion in Virology, 2012, 2, 599-605.	5.4	8
144	Detection of HIV transmission hotspots in British Columbia, Canada: A novel framework for the prioritization and allocation of treatment and prevention resources. EBioMedicine, 2019, 48, 405-413.	6.1	8

#	Article	IF	CITATIONS
145	Nef-mediated inhibition of NFAT following TCR stimulation differs between HIV-1 subtypes. Virology, 2019, 531, 192-202.	2.4	8
146	Increased CD4 : CD8 ratio normalization with implementation of current ART management guidelines. Journal of Antimicrobial Chemotherapy, 2021, 76, 729-737.	3.0	8
147	Proviral Turnover During Untreated HIV Infection Is Dynamic and Variable Between Hosts, Impacting Reservoir Composition on ART. Frontiers in Microbiology, 2021, 12, 719153.	3.5	8
148	Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy. Antiviral Therapy, 2003, 8, 91-6.	1.0	8
149	Dynamic range of Nef-mediated evasion of HLA class II-restricted immune responses in early HIV-1 infection. Biochemical and Biophysical Research Communications, 2015, 463, 248-254.	2.1	7
150	Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection. Aids, 2017, 31, 1935-1943.	2.2	7
151	Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda. Aids, 2021, 35, 1083-1089.	2.2	7
152	Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study. Journal of Antimicrobial Chemotherapy, 2022, 77, 979-988.	3.0	7
153	CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study. BMJ Open, 2021, 11, e054208.	1.9	7
154	Association of the CCR5Δ32 Mutation with Clinical Response and >5-year Survival following Initiation of First Triple Antiretroviral Regimen. Antiviral Therapy, 2005, 10, 849-853.	1.0	7
155	In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach. Journal of Virological Methods, 2017, 240, 32-41.	2.1	6
156	Modulation of TCR-dependent NFAT signaling is impaired in HIV-1 Nef isolates from elite controllers. Virology, 2019, 530, 39-50.	2.4	6
157	Clinical and evolutionary consequences of HIV adaptation to HLA. Current Opinion in HIV and AIDS, 2019, 14, 194-204.	3.8	6
158	The African natural product knipholone anthrone and its analogue anthralin (dithranol) enhance HIV-1 latency reversal. Journal of Biological Chemistry, 2020, 295, 14084-14099.	3.4	6
159	Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes. Journal of Virology, 2020, 94, .	3.4	6
160	Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial. PLoS ONE, 2012, 7, e34134.	2.5	5
161	GWATCH: a web platform for automated gene association discovery analysis. GigaScience, 2014, 3, 18.	6.4	5
162	Global Database-Driven Assessment of HIV-1 Adaptation to the Immune Repertoires of Human Populations. Journal of Virology, 2015, 89, 10693-10695.	3.4	5

#	Article	IF	CITATIONS
163	Transmitted/Founder HIV-1 Subtype C Viruses Show Distinctive Signature Patterns in Vif, Vpr, and Vpu That Are Under Subsequent Immune Pressure During Early Infection. AIDS Research and Human Retroviruses, 2016, 32, 1031-1045.	1.1	5
164	Weaker HLA Footprints on HIV in the Unique and Highly Genetically Admixed Host Population of Mexico. Journal of Virology, 2018, 92, .	3.4	5
165	Concordance of HIV transmission risk factors elucidated using viral diversification rate and phylogenetic clustering. Evolution, Medicine and Public Health, 2021, 9, 338-348.	2.5	5
166	Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada. PLoS ONE, 2017, 12, e0184848.	2.5	5
167	Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen. Antiviral Therapy, 2005, 10, 849-53.	1.0	5
168	Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals. Retrovirology, 2015, 12, 98.	2.0	4
169	Rates and Correlates of Short Term Virologic Response among Treatment-NaÃ <sup>-</sup> ve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study. Pathogens, 2019, 8, 161.	2.8	4
170	T-cell responses to sequentially emerging viral escape mutants shape long-term HIV-1 population dynamics. PLoS Pathogens, 2020, 16, e1009177.	4.7	4
171	Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy. Antiviral Therapy, 2003, 8, 395-402.	1.0	4
172	A 21-Base Pair Insertion/Duplication at Codon 69 of the HIV Type 1 Reverse Transcriptase in a Patient Undergoing Multiple Nucleoside Therapy. AIDS Research and Human Retroviruses, 2007, 23, 895-899.	1.1	3
173	HIV therapy, hepatitis C virus infection, antibiotics and obesity, a mitochondria killer mix?. Aids, 2006, 20, 1343-1345.	2.2	2
174	HLA-Associated Viral Mutations Are Common in Human Immunodeficiency Virus Type 1 Elite Controllers. Journal of Virology, 2010, 84, 1212-1212.	3.4	1
175	Using Viral Dynamics to Connect Clinical Markers of Disease Progression to Sequence Evolution during HIV Infection. AIDS Research and Human Retroviruses, 2014, 30, A223-A224.	1.1	1
176	Mutational Immune Escape in HIV-1 Infection. , 2015, , 667-706.		1
177	HIV-1 Mutational Escape from Host Immunity. , 2014, , 1-19.		1
178	HAMdetector: a Bayesian regression model that integrates information to detect HLA-associated mutations. Bioinformatics, 2022, 38, 2428-2436.	4.1	1
179	Reply to Waters et al Clinical Infectious Diseases, 2007, 45, 1244-1245.	5.8	0
180	Naturally-arising amino acid polymorphisms of HIV-1 Nef that differentially modulate downregulation of HLA-A and HLA-B molecules. Retrovirology, 2013, 10, .	2.0	0

#	Article	IF	CITATIONS
181	A method for Killer-cell Immunoglobulin-like Receptor (KIR) 3DL1/3DS1 genotyping using DNA recovered from frozen plasma. Journal of Immunological Methods, 2013, 391, 154-162.	1.4	0
182	Transmitted Escape Mutations Lead to Accelerated HIV-1 Disease Progression and Largely Define the Relative Contribution of HLA Alleles to Control. AIDS Research and Human Retroviruses, 2014, 30, A40-A40.	1.1	0
183	HIV-1 Mutational Escape from Host Immunity. , 2018, , 863-878.		0
184	Title is missing!. , 2020, 16, e1009177.		0
185	Title is missing!. , 2020, 16, e1009177.		0
186	Title is missing!. , 2020, 16, e1009177.		0
187	Title is missing!. , 2020, 16, e1009177.		0
188	Attenuated HIV-1 Nef But Not Vpu Function in a Cohort of Rwandan Long-Term Survivors. Frontiers in Virology, 0, 2, .	1.4	0